Nasdaq:US$18.56 (+0.55) | HKEX:HK$29.05 (+0.55) | AIM:£2.92 (+0.08)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer